This study, the first genome-wide association study (GWAS) to investigate the relationship between genetic markers and positive response to IL-23 inhibitor treatment in psoriasis, identified two novel variants, rs73641950 and rs6627462, that reached genome-wide significance. The gene discussed is IL23A; the disease is psoriasis.